Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.88 |
| ▸ | MAPT | P10636 | 5/20 | 0.88 |
| ▸ | POLB | P06746 | 3/20 | 0.88 |
| ▸ | MEN1 | O00255 | 2/20 | 0.88 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.88 |
| ▸ | NAMPT | P43490 | 2/20 | 0.78 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.72 |
| ▸ | RAB9A | P51151 | 9/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.57 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.57 |
| ▸ | CDK2 | P24941 | 1/20 | 0.57 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.57 |
| ▸ | CASP3 | P42574 | 1/20 | 0.56 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.56 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.56 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL651929 | 0.94 | NPC1 (1.00) | NPC1MAPTPOLBMEN1KMT2A | |
| SCHEMBL31054249 | 0.94 | NPC1 (1.00) | NPC1MAPTPOLBMEN1KMT2A | |
| SCHEMBL5661569 | 0.93 | NPC1 (0.81) | NPC1MAPTPOLBMEN1KMT2A | |
| SCHEMBL5655823 | 0.91 | NPC1 (0.88) | NPC1MAPTPOLBMEN1KMT2A | |
| SCHEMBL5656486 | 0.89 | NPC1 (0.74) | NPC1MAPTPOLBMEN1KMT2A | |
| SCHEMBL164852 | 0.88 | NAMPT (1.00) | NPC1MAPTPOLBMEN1KMT2A | |
| SCHEMBL28741230 | 0.87 | NPC1 (0.81) | NPC1MAPTPOLBMEN1KMT2A | |
| SCHEMBL29639124 | 0.87 | NPC1 (0.81) | NPC1MAPTPOLBMEN1KMT2A | |
| SCHEMBL5657576 | 0.86 | NPC1 (0.78) | NPC1MAPTPOLBMEN1KMT2A | |
| SCHEMBL5658555 | 0.86 | NPC1 (0.78) | NPC1MAPTPOLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4228630-B1 | NLRP3 ACTIVATORS FOR USE IN THE TREATMENT OF INFECTIOUS DISEASES OR CANCER BY ACTIVATING NLRP3 INFLAMMASOME | UNIV FREIBURG ALBERT LUDWIGS (DE) | 2025-03-05 | — | — | EP | claimed |
| US-20240277658-A1 | NLRP3 ACTIVATORS FOR USE IN THE TREATMENT OF INFECTIOUS DISEASES OR CANCER BY ACTIVATING NLRP3 INFLAMMASOME | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2024-08-22 | — | — | US | claimed |
| EP-0682656-A1 | USE OF PHENYL HETEROARYL UREAS AS 5HT 2C? RECEPTOR ANTAGONISTS AND UREA COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 1995-11-22 | — | — | EP | claimed |
| WO-1994018170-A1 | USE OF PHENYL HETEROARYL UREAS AS 5HT2C RECEPTOR ANTAGONISTS AND UREA COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 1994-08-18 | — | — | WO | claimed |
| EP-4228630-B1 | NLRP3 ACTIVATORS FOR USE IN THE TREATMENT OF INFECTIOUS DISEASES OR CANCER BY ACTIVATING NLRP3 INFLAMMASOME | UNIV FREIBURG ALBERT LUDWIGS (DE) | 2025-03-05 | — | — | EP | disclosed |
| US-20240277658-A1 | NLRP3 ACTIVATORS FOR USE IN THE TREATMENT OF INFECTIOUS DISEASES OR CANCER BY ACTIVATING NLRP3 INFLAMMASOME | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2024-08-22 | — | — | US | disclosed |
| WO-2022079246-A1 | NLRP3 ACTIVATORS FOR USE IN THE TREATMENT OF INFECTIOUS DISEASES OR CANCER BY ACTIVATING NLRP3 INFLAMMASOME | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2022-04-21 | — | — | WO | disclosed |
| EP-3984535-A1 | NLRP3 ACTIVATORS FOR USE IN THE TREATMENT OF INFECTIOUS DISEASES OR CANCER BY ACTIVATING NLRP3 INFLAMMASOME | Albert-Ludwigs-Universität Freiburg (DE) | 2022-04-20 | — | — | EP | disclosed |
| US-7285563-B2 | Heteroaromatic urea derivatives as VR-1 receptor modulators for treating pain | MERCK SHARP & DOHME LTD. (GB) | 2007-10-23 | — | — | US | disclosed |
| US-20050107388-A1 | Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain | MERCK SHARP & DOHME LTD. (GB) | 2005-05-19 | — | — | US | disclosed |
| EP-1490340-A1 | HETEROAROMATIC UREA DERIVATIVES AS VR-1 RECEPTOR MODULATORS FOR TREATING PAIN | MERCK SHARP & DOHME LTD. (GB) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003080578-A1 | HETEROAROMATIC UREA DERIVATIVES AS VR-1 RECEPTOR MODULATORS FOR TREATING PAIN | MERCK SHARP & DOHME LIMITED (GB) | 2003-10-02 | — | — | WO | disclosed |
| EP-0682656-A1 | USE OF PHENYL HETEROARYL UREAS AS 5HT 2C? RECEPTOR ANTAGONISTS AND UREA COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 1995-11-22 | — | — | EP | disclosed |
| WO-1994018170-A1 | USE OF PHENYL HETEROARYL UREAS AS 5HT2C RECEPTOR ANTAGONISTS AND UREA COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 1994-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107388-A1 | Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain | ARRB1, OPRL1, CNR1 | NPC1 959/4885MAPT 4195/4885POLB 3281/4885 |
| US-20240277658-A1 | NLRP3 ACTIVATORS FOR USE IN THE TREATMENT OF INFECTIOUS DISEASES OR CANCER BY ACTIVATING NLRP3 INFLAMMASOME | NLRP3, PYCARD, NLRP1 | NPC1 146/4885MAPT 766/4885POLB 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.